JBI 1527
Alternative Names: JBI-1527; JTi - Jubilant TherapeuticsLatest Information Update: 16 Jun 2021
Price :
$50 *
At a glance
- Originator Jubilant Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Jun 2021 Jubilant Therapeutics plans to file an IND application with the US FDA for Cancer in the first half of 2022 (Jubilant Therapeutics pipeline, June 2021)
- 14 Jun 2021 Jubilant Therapeutics plans a clinical trial for Cancer in USA (Jubilant Therapeutics pipeline, June 2021)
- 11 Jun 2021 JBI 1527 is available for licensing as of 11 Jun 2021. https://www.jubilanttx.com/collaborations